| Daniel G Snediker, MD | |
|
601 Colliers Way, Weirton, WV 26062-5014 | |
| (330) 493-4443 | |
| (330) 493-8677 |
| Full Name | Daniel G Snediker |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 20 Years |
| Location | 601 Colliers Way, Weirton, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982634267 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 22345 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Poinciana Medical Center | Kissimmee, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Medicine Services Of Fl Llc | 8426413931 | 161 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Howard Hughes Medical Institute (HHMI) scientists who participated in the project say the sequencing of the genomes of the parasitic protozoa that cause Chagas disease, African sleeping sickness, and leishmaniasis, could significantly impact world health. Some of the genes discovered may prove to be good drug and vaccine targets.
As the latest in a series of studies, researchers at Plymouth University, National Institutes of Health and University of California, Riverside, have shown the ability of a vaccine vector based on a common herpesvirus called cytomegalovirus (CMV) expressing Ebola virus glycoprotein (GP), to provide protection against Ebola virus in the experimental rhesus macaque, non-human primate (NHP) model.
A study from the University of Colorado School of Medicine shows patients with Medicaid insurance seeking care in an emergency department may be driven by lack of alternatives instead of the severity of their illness. The study is published in the Journal of General Internal Medicine.
› Verified 9 days ago
| Entity Name | Emergency Medicine Services Of Fl Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043917180 PECOS PAC ID: 8426413931 Enrollment ID: O20230504001881 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Howard Hughes Medical Institute (HHMI) scientists who participated in the project say the sequencing of the genomes of the parasitic protozoa that cause Chagas disease, African sleeping sickness, and leishmaniasis, could significantly impact world health. Some of the genes discovered may prove to be good drug and vaccine targets.
As the latest in a series of studies, researchers at Plymouth University, National Institutes of Health and University of California, Riverside, have shown the ability of a vaccine vector based on a common herpesvirus called cytomegalovirus (CMV) expressing Ebola virus glycoprotein (GP), to provide protection against Ebola virus in the experimental rhesus macaque, non-human primate (NHP) model.
A study from the University of Colorado School of Medicine shows patients with Medicaid insurance seeking care in an emergency department may be driven by lack of alternatives instead of the severity of their illness. The study is published in the Journal of General Internal Medicine.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel G Snediker, MD 4535 Dressler Rd Nw, Canton, OH 44718-2545 Ph: (330) 493-4443 | Daniel G Snediker, MD 601 Colliers Way, Weirton, WV 26062-5014 Ph: (330) 493-4443 |
News Archive
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
Howard Hughes Medical Institute (HHMI) scientists who participated in the project say the sequencing of the genomes of the parasitic protozoa that cause Chagas disease, African sleeping sickness, and leishmaniasis, could significantly impact world health. Some of the genes discovered may prove to be good drug and vaccine targets.
As the latest in a series of studies, researchers at Plymouth University, National Institutes of Health and University of California, Riverside, have shown the ability of a vaccine vector based on a common herpesvirus called cytomegalovirus (CMV) expressing Ebola virus glycoprotein (GP), to provide protection against Ebola virus in the experimental rhesus macaque, non-human primate (NHP) model.
A study from the University of Colorado School of Medicine shows patients with Medicaid insurance seeking care in an emergency department may be driven by lack of alternatives instead of the severity of their illness. The study is published in the Journal of General Internal Medicine.
› Verified 9 days ago
Dr. Christian Bosquet, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 917-346-5756 | |
Timothy G Lane, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 330-493-4443 Fax: 330-493-8677 | |
Dr. Joshua Tad Lucas, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 330-493-4443 | |
Mitchell Fuscardo, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 330-493-4443 | |
Todd Fijewski, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 330-493-4443 Fax: 330-493-8677 | |
Dr. Daryl Trusty, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 304-797-6095 Fax: 304-797-6090 | |
Kelly B Close, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Colliers Way, Weirton, WV 26062 Phone: 330-493-4443 Fax: 330-493-8677 |